Figures & data
Figure 1 Vertebral bodies before (A) and after (B) treatment for 14 months for a child with Type I osteogenesis imperfecta.
![Figure 1 Vertebral bodies before (A) and after (B) treatment for 14 months for a child with Type I osteogenesis imperfecta.](/cms/asset/f56af8b3-596a-4245-ab12-50bdee1e551c/dtcr_a_35788_f0001_b.jpg)
Figure 2 Mean serum alkaline phosphatase levels during the 36-month study for the intramuscular and intravenous neridronate regimens.
Abbreviations: NER, neridronate; i.v., intravenous; i.m., intramuscular.
![Figure 2 Mean serum alkaline phosphatase levels during the 36-month study for the intramuscular and intravenous neridronate regimens.](/cms/asset/b84d5462-1bad-48ed-990b-863cb9dcf0f2/dtcr_a_35788_f0002_b.jpg)
Figure 3 Double-blind phase: VAS trends from baseline to day 40 in patients with complex regional pain syndrome type I treated with neridronate or placebo.
Abbreviations: VAS, visual analog scale; SD, standard deviation.
![Figure 3 Double-blind phase: VAS trends from baseline to day 40 in patients with complex regional pain syndrome type I treated with neridronate or placebo.](/cms/asset/35d3f569-011e-45da-9b25-64728dfb0915/dtcr_a_35788_f0003_b.jpg)
Figure 4 VAS values at the end of the follow-up period of the double-blind phase (day −10) and after the treatment course with intravenous neridronate in patients with complex regional pain syndrome type I.
Abbreviations: VAS, visual analog scale; SD, standard deviation.
![Figure 4 VAS values at the end of the follow-up period of the double-blind phase (day −10) and after the treatment course with intravenous neridronate in patients with complex regional pain syndrome type I.](/cms/asset/4f467452-451d-4e7b-830f-112bd57df52c/dtcr_a_35788_f0004_b.jpg)